Quoin director granted 21,709 ADS options

Quoin Pharmaceuticals director Dennis Langer received a grant of stock options linked to American Depositary Shares (ADSs).

Rhea-AI Filing Summary

Quoin Pharmaceuticals director Dennis Langer received a grant of stock options linked to American Depositary Shares (ADSs). On February 4, 2026, he was awarded options to acquire 21,709 ADSs at an exercise price of $7.37 per ADS. Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals. The options vest over four years, with 20% vesting on each of February 4, 2027, 2028, and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, Langer beneficially owns 21,709 derivative securities directly.

Insider Trade Summary

Grant/Award: 21,709 shares

Grant/Award 1 txn

Insider LANGER DENNIS

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	21,709	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 21,709 contracts (Direct)

Footnotes (2)

1. F1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.
2. F2. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Quoin Pharmaceuticals (QNRX) report for Dennis Langer?

Quoin Pharmaceuticals reported a stock option grant to director Dennis Langer. On February 4, 2026, he received options for 21,709 ADSs at a $7.37 exercise price, vesting over four years, giving him direct beneficial ownership of these derivative securities if he exercises them.

How many Quoin (QNRX) ADS options were granted to director Dennis Langer?

Dennis Langer was granted options on 21,709 Quoin ADSs. The award is structured as a derivative security, giving him the right to buy 21,709 ADSs at a fixed $7.37 exercise price, subject to a multi-year vesting schedule running from 2027 through 2030.

What is the vesting schedule for Dennis Langer’s Quoin (QNRX) option grant?

The 21,709 ADS options vest in four annual installments. Twenty percent vests on each of February 4, 2027, 2028, and 2029, with the remaining 40% vesting on February 4, 2030, aligning Langer’s potential equity ownership with longer-term company performance.

What does each Quoin (QNRX) ADS represent in Dennis Langer’s option grant?

Each ADS in Dennis Langer’s grant represents thirty-five ordinary shares. The option terms, including the 21,709 underlying securities and the $7.37 exercise price, are all expressed in ADS units, linking his potential equity stake to these depositary share conventions.

Is Dennis Langer’s Quoin (QNRX) option grant reported as directly owned?

Yes, the 21,709 ADS options are reported as directly owned by Dennis Langer. The filing classifies his ownership form as direct, with no footnote disclaimers transferring voting or investment authority to another entity, indicating personal beneficial ownership of the derivative position.

What role does Dennis Langer hold at Quoin Pharmaceuticals (QNRX) in this Form 4?

Dennis Langer is identified as a director of Quoin Pharmaceuticals. The Form 4 indicates his relationship box checked as director, with no officer or 10% owner status marked, and reports the stock option grant as part of his equity-based compensation in that governance role.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LANGER DENNIS

(Last) (First) (Middle)

C/O QUOIN PHARMACEUTICALS LTD.,

42127 PLEASANT FOREST COURT

(Street)

ASHBURN VA 20148

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [ QNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$7.37(1)	02/04/2026		A		21,709(1)		(2)	02/04/2036	ADS	21,709(1)	$0	21,709(1)	D

Explanation of Responses:

1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

2. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

	/s/ Dennis Langer	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.